Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
Cancer Medicine · 2023-06 · 12 (12) · 13135-13144
DOI: 10.1002/cam4.5996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.04.2023. Verfasst von Tomotaka Suzuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Paraproteinemias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD).
Methods
We retrospectively measured serum SARS‐CoV‐2 antibodies against the spike protein (S‐IgG) after the second and third mRNA vaccine doses (doses 2 and 3, respectively) in 109 patients with PCD. We evaluated the proportion of patients with an adequate humoral response (defined as S‐IgG titers ≥300 antibody units/mL).
Results
Although active anti‐myeloma treatments prior to vaccination had a significantly negative impact on adequate humoral response, specific drug subclasses including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies were not negatively associated, except for B‐cell maturation antigen‐targeted therapy. Dose 3 (booster vaccination) led to significantly higher S‐IgG titers and more patients acquired an adequate humoral response. Furthermore, evaluation of vaccine‐induced cellular immune response in patients using T‐spot Discovery SARS‐CoV‐2 kit, revealed an enhanced cellular immune response after Dose 3.
Conclusions
This study highlighted the significance of booster SARS‐CoV‐2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine‐induced humoral immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Scientific Affairs, Sysmex Corporation, Kobe, Japan.
- Clinical Research Management Center, Nagoya City University Hospital, Nagoya, Japan.
ORCID-Profile: Tomotaka Suzuki, Shigeru Kusumoto, Hiroya Hashimoto, Masaki Ri
Zitieren
APA
Suzuki, T., Kusumoto, S., Kamezaki, Y., Hashimoto, H., Nishitarumizu, N., Nakanishi, Y., Kato, Y., Kawai, A., Matsunaga, N., Ebina, T., Nakamura, T., Marumo, Y., Oiwa, K., Kinoshita, S., Narita, T., Ito, A., Inagaki, A., Ri, M., Komatsu, H., …, & Iida, S. (2023). Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia. Cancer Medicine, 12(12), 13135-13144. https://doi.org/10.1002/cam4.5996
Vancouver
Suzuki T, Kusumoto S, Kamezaki Y, Hashimoto H, Nishitarumizu N, Nakanishi Y, et al. Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia. Cancer Medicine. 2023;12(12):13135-13144. doi:10.1002/cam4.5996
BibTeX
@article{Suzuki2023,
author = {Suzuki, Tomotaka and Kusumoto, Shigeru and Kamezaki, Yoshiko and Hashimoto, Hiroya and Nishitarumizu, Nozomi and Nakanishi, Yoko and Kato, Yukiyasu and Kawai, Akimi and Matsunaga, Naohiro and Ebina, Toru and Nakamura, Tomoyuki and Marumo, Yoshiaki and Oiwa, Kana and Kinoshita, Shiori and Narita, Tomoko and Ito, Asahi and Inagaki, Atsushi and Ri, Masaki and Komatsu, Hirokazu and Aritsu, Takashi and Iida, Shinsuke},
title = {Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {12},
pages = {13135--13144},
doi = {10.1002/cam4.5996}
}
EUVIMED